ArticleAdvanced healthcare materials2026
Modular Control of PEG-Poly(2-Oxazoline) Co-Assembly Enables Tunable Aggregate Properties for Intraocular Pressure Management.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Poly(2-oxazoline) (POx) polymers are hydrophilic and biocompatible materials with tunable physicochemical properties for biomedical use. Postoperative hypotony, which currently lacks approved pharmacological or device-based treatment, requires minimally invasive and controllable methods for temporary intraocular pressure restoration. Herein, we present a modular strategy to control POx aggregation via thermally triggered co-assembly with thermoswitchable poly(2-n-propyl-2-oxazoline) (PnPrOx) and hydrophilic PEG-modified PnPrOx (PnPrOx-PEG). These mixtures remain dissolved at low temperatures but aggregate at physiological temperatures because of the thermo-switchable behavior of the PnPrOx segments, with PEG content modulating particle size, dispersibility, and fusion. Based on in vivo compositional screening in rabbits, we highlight a 98:2 (w/w) PnPrOx:PnPrOx-PEG formulation (POx2P) that induces transient intraocular pressure elevation without persistent turbidity or deposition. In a trabeculectomy-induced hypotony model, POx2P restored intraocular pressure without adverse effects. Microscopy and in vivo imaging suggest that this formulation forms flow-responsive aggregates that transiently occlude aqueous outflow pathways. We established a compositionally tunable and injectable POx platform for in situ aggregation and pressure modulation, offering a clinically relevant approach for localised intraocular therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.